6 terminated. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 6 |
| Phase 2 | 1 | Terminated 1 |
Follow Relapsing Chronic Myelogenous Leukemia: new trials by email Literature Review of Relapsing Chronic Myelogenous Leukemia trials Research Report on Relapsing Chronic Myelogenous Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate dasatinib, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Terminated | National Cancer Institute (NCI) | 4 | 2011-09-01 | 2014-04-02 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia SJG-136 - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Terminated | National Cancer Institute (NCI) | 25 | 2005-12-01 | 2013-09-30 |
| Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia imatinib mesylate, temsirolimus, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 21 | 2005-04-01 | 2013-01-14 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia alvocidib - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 88 | 2004-10-01 | 2013-06-04 |
| Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 7 | 2002-09-01 | 2017-02-15 |
Blast Crisis (5) · Congenital Abnormalities (3) · Leukemia, Myeloid, Accelerated Phase (3) · Leukemia, Myeloid, Acute (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Chronic-Phase (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Immunoblastic Lymphadenopathy (1) · Intraocular Lymphoma (1) · Leukemia, Basophilic, Acute (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Eosinophilic, Acute (1)
Bone Marrow Diseases (6) · Chronic Disease (6) · Disease Attributes (6) · Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Leukemia (6) · Leukemia, Myeloid (6) · Myeloproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Carcinogenesis (5) · Cell Transformation, Neoplastic (5) · Neoplastic Processes (5)
1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione) (1) · Cyclosporine (1) · Dasatinib (1) · Dexrazoxane (1) · Doxorubicin (1) · Flow Cytometry (1) · Imatinib Mesylate (1) · Interleukin-2 (1) · Razoxane (1) · Sirolimus (1) · Vincristine (1) · aldesleukin (1) · alvocidib (1) · obatoclax (1) · temsirolimus (1)
National Cancer Institute (NCI) (5) · Fred Hutchinson Cancer Center (1)
United States (6) · Canada (1)
Christopher Porter (1) · Farhad Ravandi-Kashani (1) · Gunnar Ragnarsson (1) · Richard Aplenc (1) · Tiong Ong (1) · William Blum (1)
P01CA018029 (1), P30CA046934 (1), R21CA112936 (1), U01CA062461 (1), U01CA076576 (1), U01CA097452 (1)